Loading...
•
Mar 31, 2024
Compass Q1 2024 Earnings Report
Compass Therapeutics reported first quarter 2024 financial results and provided a corporate update.
Key Takeaways
Compass Therapeutics reported a net loss of $10.8 million for the first quarter of 2024. The company's cash and marketable securities were $156.3 million as of March 31, 2024, extending the cash runway into late 2026.
Compass continues to make considerable progress across all of clinical programs.
FDA granted Fast Track Designation for CTX-009.
Top-line data from COMPANION-002 is expected in less than a year.
Top-line data from the first part of COMPANION-003 is expected by mid-year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...